NR3C2 and diabetes mellitus: Several notable novel agents have been recently reported to have benefits for reducing progression to DKD among diabetes mellitus (DM) patients, and these agents include sodium-glucose cotransporter 2 inhibitors (SGLT2is), glucagon-like peptide-1 (GLP-1) agonists, a selective endothelin-1 receptor antagonist, and a nonsteroidal mineralocorticoid receptor antagonist.